An observational study in Oropharyngeal Cancer, sponsored by Sanford Health. Active, not recruiting at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-05.
Sponsored by Sanford Health · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 235 studies in Oropharyngeal Neoplasms with a site in United States — 63 open to participants now, 98 under way, 11 of them phase 3. Oropharyngeal Neoplasms · United States.
Among the 235 studies in Oropharyngeal Neoplasms with a site in United States, this one is the 25th largest by enrollment of the 36 observational ones that give a count, is one of 21 that started in 2018, is one of 36 observational ones, reaches primary completion later than 39 of the 97 other live ones, and was the 124th registered.
370 studies on the registry are indexed under Oropharyngeal Neoplasms; 104 are open to participants now.
Browse Oropharyngeal Neoplasms studies →63 of the 235 studies in Oropharyngeal Neoplasms with a site in United States are open now. Recruiting first, the newest first:
National Cancer Institute (NCI) · Sites in United States
Ages 18+
University of Maryland, Baltimore · Sites in United States
Ages 18+
Metaclipse Therapeutics Corporation · Sites in United States
Ages 18+
Corbus Pharmaceuticals Inc. · Sites in United States, Austria, Belgium and 11 more countries
Ages 18+
OHSU Knight Cancer Institute · Sites in United States
Ages 18–89
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 89 Oropharyngeal Neoplasms studies recruiting now, 76 (85%) set no upper age limit and 5 (6%) stop at 75 or younger; none take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
235 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 45 · Phase 2 108 · Phase 3 21 · Phase 4 3
First in 1995; this study’s year is marked. 21 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 75 is below the median of 142 across 75 observational studies indexed under Oropharyngeal Neoplasms.
Median enrollment 42 across the 189 interventional studies, 205 across the 36 observational. Of the 120 that completed or were terminated, 53 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 235 have an industry lead sponsor. The 10 most frequent:
Sanford Health is the lead sponsor of 40 studies on the registry; 9 are open to participants now.
Sanford Health has 2 studies filed under Oropharyngeal Neoplasms — fewer than ten, so there is no comparison to draw.
31 of the studies in Oropharyngeal Neoplasms with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01266044Phase 3M.D. Anderson Cancer CenterControlled Trial Of Acupuncture To Prevent Radiation-Induced Xerostomia | 2026-12-31 |
| NCT02215265Phase 3Lisette NixonPost-operative Adjuvant Treatment for HPV-positive Tumours (PATHOS) | 2027-10 |
| NCT04609280University of Maryland, BaltimoreSelective Avoidance of Nodal VolumEs at Minimal Risk (GCC 20110) | 2026-12 |
| NCT05312710Aveta Biomics, Inc.Safety and Efficacy of APG-157 in Head and Neck Cancer | 2026-12 |
| NCT06319963Theravectys S.A.A Study to Evaluate Lenti-HPV-07 Immunotherapy Against HPV+ Cervical or Oropharyngeal Cancer | 2026-12 |
Add all 31 to your calendar (.ics) → With an account.
Among the 235 studies in Oropharyngeal Neoplasms with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A prospective, observational study evaluating the durability of local/regional control of previously published de-escalated radiotherapy protocols for patients with P16 positive oropharynx cancers who have minimal nicotine exposure who are not current uses (\< 10 pack year smoking history; \< 10 year history of any nicotine product [electronic cigarette, chewing tobacco]). Quality of Life measures will also be collected.
This is a prospective, single-site, observational study in head and neck cancer participants. The purpose of this study is to provide a systematic platform to analyze, interpret, and track radiation dose de-escalation therapy and associated participant outcomes from treatments identified by these results.
Participants will be asked to complete quality of life questionnaires at regular time points before, during, and after treatment.
Patients with HPV positive oropharynx cancers who have minimal nicotine exposure who are not current uses (\< 10 pack year smoking history; \< 10 year history of any nicotine product [electronic cigarette, chewing tobacco]).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Human Papilloma Virus (HPV) associated cancer as determined by positive p16 immunohistochemistry
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The durability of local disease control of de-escalated radiotherapy protocols in the community cancer center setting.
Number of participants who remain disease free from the end of treatment to 5 years after treatment.
Time frame: End of treatment to 5 years after end of treatment
Plan to share: No
No publications or documents are linked to this record.
Started Oct 2018 (actual). Primary completion is estimated for Jul 2027, 105 months after the start.
Of 47 observational studies under Oropharyngeal Neoplasms, half reached primary completion within 110 months of starting (the median), counting those still running; a quarter within 40. This study's planned 105 months is close to that.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 5, 2026: primary completion Jul 2026 → Jul 2027 and completion Dec 2026 → Dec 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Sanford Health